SEC Form 4 · accession 0001209191-18-057421
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amit Sachdev
Officer — EVP, CRO
Period of report
Nov 2, 2018
Accepted (ET)
Nov 6, 2018 · 4:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2018 | M | 2,155 | $91.05 | A | 48,817 | D | |
| Common StockF2,F3 | Nov 2, 2018 | S | 600 | $171.93 | D | 48,217 | D | |
| Common StockF3,F4 | Nov 2, 2018 | S | 1,255 | $172.81 | D | 46,962 | D | |
| Common Stock | Nov 2, 2018 | S | 100 | $173.35 | D | 46,862 | D | |
| Common Stock | Nov 2, 2018 | S | 100 | $175.31 | D | 46,762 | D | |
| Common Stock | Nov 2, 2018 | S | 100 | $176.04 | D | 46,662 | D | |
| Common Stock | Nov 5, 2018 | M | 1,941 | $86.52 | A | 48,603 | D | |
| Common StockF3,F5 | Nov 5, 2018 | S | 300 | $172.70 | D | 48,303 | D | |
| Common StockF3,F6 | Nov 5, 2018 | S | 1,213 | $173.74 | D | 47,090 | D | |
| Common StockF3,F7 | Nov 5, 2018 | S | 428 | $174.41 | D | 46,662 | D | |
| Common Stock | holding | — | — | — | 12,215 | I | Held in Trust | |
| Common Stock | holding | — | — | — | 882 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F8 | $91.05 | Nov 2, 2018 | M | 2,155 | A | — | Feb 1, 2026 | Common Stock | 2,155 | 10,777 | D |
| Stock Option (Right to Buy)F9 | $86.52 | Nov 5, 2018 | M | 1,941 | A | — | Feb 2, 2027 | Common Stock | 1,941 | 17,475 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $171.93 (range $171.25 to $172.24).
- F3Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $172.81 (range $172.32 to $173.27).
- F5Open market sales reported on this line occurred at a weighted average price of $172.70 (range $172.16 to $173.12).
- F6Open market sales reported on this line occurred at a weighted average price of $173.74 (range $173.28 to $174.15).
- F7Open market sales reported on this line occurred at a weighted average price of $174.41(range $174.31 to $174.50).
- F8The option vests in 16 quarterly installments from 2/2/2016.
- F9The option vests in 16 quarterly installments from 02/03/2017.